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Background: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the
management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor
subsets most amenable to angiogenesis modulation are lacking.
Methods: We profiled expession of 24526 genes by means of whole genome 24 K DASL (c-DNA-mediated,
Annealing, Selection and Ligation) arrays, (Illumina, CA) in 16 bevacizumab-treated patients with advanced colon
cancer (Test set). Genes with correlation to 8-month Progression-free status were studied by means of qPCR in two
independent colon cancer cohorts: 49 patients treated with bevacizumab + chemotherapy (Bevacizumab qPCR set)
and 72 patients treated with chemotherapy only (Control qPCR set). Endpoints were best tumor response before
metastasectomy (ORR) and progression-free survival (PFS).
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Results: Five genes were significantly correlated to 8-month progression-free status in the Test set: overexpression of
KLF12 and downregulation of AGR2, ALDH6A1, MCM5, TFF2. In the two independent datasets, irinotecan- or
oxaliplatin-based chemotherapy was administered as first-line treatment and metastasectomies were subsequently
applied in 8-14% of patients. No prognostically significant gene classifier encompassing all five genes could be validated
in the Bevacizumab or Control qPCR sets. The complex gene expression profile of all-low tumor (ALDH6A1 + TFF2 +
MCM5) was strongly associated with ORR in the Bevacizumab qPCR set (ORR 85.7%, p = 0.007), but not in the Control
set (ORR 36.4%, p = 0.747). The Odds Ratio for response for the all-low tumor (ALDH6A1 + TFF2 +MCM5) profile versus
any other ALDH6A1 + TFF2 +MCM5 profile was 15 (p = 0.018) in the Bevacizumab qPCR set but only 0.72 (p = 0.63) in
the Control set. The tumor expression profile of (KLF12-high + TFF2-low) was significantly associated with PFS only in
the Bevacizumab qPCR set: bevacizumab-treated patients with (KLF12-high + TFF2-low) tumors had superior PFS
(median 14 months, 95% CI 2-21) compared to patients with any other (KLF12 + TFF2) expression profile (median PFS
7 months, 95% CI 5-10, p = 0.021). The Hazard Ratio for disease progression for (KLF12-high + TFF2-low) versus any other
KLF12 + TFF2 expression profile was 2.92 (p = 0.03) in the Validation and 1.29 (p = 0.39) in the Control set.
Conclusions: Our «three-stage» hypothesis-generating study failed to validate the prognostic significance of a
five-gene classifier in mCRC patients. Exploratory analyses suggest two gene signatures that are potentially associated
with bevazicumab benefit in patients with advanced colon cancer.
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The high cost of targeted therapies as well as their concep-
tual definition as «targeting» specific molecular aberra-
tions mandate the use of biomarkers in modern oncology
practice [1]. Biomarkers are tumor and host characteristics
that either define the natural course of a malignancy irre-
spective of therapy (prognostic) or the probability of pa-
tient benefit from a therapy administered (predictive) [2].
Although both are clinically relevant, less progress has
been made in the field of the latter.
Angiogenesis is the process of new blood vessel forma-
tion and is pivotal for tumor growth, invasion and metas-
tases [3]. Bevacizumab, a humanized monoclonal antibody
that binds and neutralizes one of the main effectors of ma-
lignant angiogenesis, the Vascular Endothelial Growth
Factor (VEGF), has been licensed for the treatment of pa-
tients with metastatic colorectal cancer combined with
chemotherapy [4]. However, the rather modest improve-
ment in response and survival outcomes achieved indicate
the rich tumor heterogeneity and the probability that only
a subset of tumors are amenable to VEGF modulation.
The molecular characterization of tumors responsive to
bevacizumab remains the Holy Grail for a worlwide com-
munity of investigators.
Genomic technologies are being widely used to study
tumors at the molecular level. Since the extraction of
RNA from formalin-fixed, paraffin-embedded (FFPE)
tumor tissue has been optimized, microarray-based mul-
tigene expression profiling platforms have been devel-
oped for the identification of molecular signatures
associated with various tumor characteristics [5]. The lar-
ger scale availabilty and more straightforward feasibility
of performing quantitative PCR (qPCR) assays commonlyled to attempts to adapt microarray signatures to qPCR
methodologies.
In this study, we used a microarray platform to profile
the expression of 24526 genes in a test set of 16 patients
with metastatic colon cancer treated with bevacizumab,
aiming to identify a select set of genes associated with
superior outcome on bevacizumab. We then studied the
expression of these genes using qPCR in an independent
set of patients who received bevacizumab and in a con-
trol set of patients who were treated with chemotherapy
only, in order to confirm their significance and to dissect
their potential predictive from prognostic utility.
Methods
Patients with chemonaive metastatic colon cancer who re-
ceived first-line standardized chemotherapy protocols with
or without bevacizumab between 2005 and 2009 in oncol-
ogy centers affiliated with the Hellenic Cooperative Oncol-
ogy Group (HeCOG), consented for the research use of
their biologic material. FFPE blocks were fully annotated
with clinicopathologic characteristics. The translational re-
search protocol was approved by the Scientific Commitee,
Papageorgiou Hospital, Thessaloniki, 185/8-10-2013. The
patient sets consisted of three cohorts: a) the Test set
(N = 16, patients treated with chemotherapy and bevacizu-
mab) in which FFPE microarray analysis was performed in
order to identify candidate genes predictive of bevacizu-
mab benefit, b) the Bevacizumab qPCR set (N = 49, an in-
dependent cohort of patients treated with chemotherapy
and bevacizumab) and the Control qPCR set (N = 72, pa-
tients treated with chemotherapy without bevacizumab).
All patients had a performance status of 0-1. In the latter
two independent sets, expression of the selected genes
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tified by means of qPCR (Additional file 1: Figure S1 for
REMARK diagram).
For RNA extraction from FFPE tumors, H&E sections
were histologically reviewed and areas containing >50%
tumor cells were marked; these were macrodissected
from serial unstained sections at 8um after deparaffini-
zation and submitted for RNA extraction with the
RNeasy FFPE Kit (Qiagen, Hilden, D). For the Test Set,
two series of RNA samples were prepared; one of these
was submitted for Illumina profiling. RNA samples from
the Test, Bevacizumab qPCR and the Control qPCR Sets
were processed for reverse transcription and first strand
cDNA synthesis with the Superscript III and random
hexamers (Invitrogen/Life Technologies). All reagents
and systems were used according to the instructions of
the manufacturers. cDNAs were normalized at 25 ng/ul
and stored at -20°C until use.
Microarray methodology and analysis
We performed global gene expression profiling on the 16
patients of our test set using whole genome DASL
(cDNA-mediated, Annealing, Selection, and Ligation) ar-
rays (Illumina, CA), covering more than 24,000 tran-
scripts. This technology overcomes the challenges of
profiling partially degraded RNA, often extracted from
FFPE samples and provides high-quality gene expression
data [6]. We isolated 250 ng of total RNA in a concentra-
tion of 25 ng/μl, as required by Expression Analysis Inc
(Durham, NC). The A260/A280 ratio of each RNA speci-
men exceeded 1.6. Outlier exclusion was based on the
percent present call of the samples; detection rate
>12000 transcripts. Microarray experiments were carried
out at Expression Analysis Inc (Durham, NC) according
to the manufacturer’s recommendations. The microarray
data have been submitted to Gene Expression Omnibus
as study GSE53127 and can be viewed at: http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53127.
5-gene predictor validation with qPCR
The 5-gene predictor was evaluated on cDNA samples
from the Bevacizumab qPCR and Control sets with qPCR
and hydrolysis probes (TaqMan® MGB probes, Applied
Biosystems/Life Technologies). The following premade
assays were selected for amplicons matching the regions
targeted by corresponding Illumina probes (assay ID,
NM-reference, exon spanning, location, size): AGR2
Hs00356521_m1 (NM_006408.3, ex 7-8, 665, 69 bp);
ALDH6A1 Hs00194421_m1 (NM_005589.2, ex 11-12,
1607, 131 bp); KLF12 Hs00273134_m1 (NM_007249.4,
ex 6-7, 1089, 100 bp); MCM5 Hs01052142_m1
(NM_006739.3, ex 16-17, 2197, 70 bp); and, TFF2
Hs00989207_m1 (NM_005423.4, ex 3-4, 520, 68 bp).
For normalization and relative expression assessment,3 premade TaqMan® MGB assays for endogenous control
transcripts were used: #4333767 F for GUSB; Hs00
183533_m1 for IPO8; and Hs00427620_m1 for TBP.
Samples were run in duplicates, in 10ul reactions (2ul
cDNA template per reaction) in an ABI7900HT real time
PCR system under default conditions. A commercially
available reference RNA derived from multiple trans-
formed cell lines (TaqMan® Control Total RNA, cat. no
4307281, Applied Biosystems) was applied in multiple
positions in each run as positive control and for inter-run
evaluation of PCR assay efficiency. No-template controls
were also included. Samples were run in duplicates, at
least in two metachronous runs. To obtain linear Relative
Quantification (RQ) values, relative expression was as-
sessed as (40-dCT), as previously described, whereby
dCT (or deltaCT) was calculated as (average target
CT) – (average endogenous control CT) from all eligible
measurements [7]. Samples were considered eligible for
analysis when (a) both endogenous control CTs in du-
plicates were <36 and when duplicate dCT’s for the
same sample within the same run were <0.75. The effi-
ciency of all assays was considered as comparable, since
the difference between inter-run RQ values for the ref-
erence RNA sample was <1 for all assays. Upon testing
for target RQ value compliance per sample with each
endogenous control, TPB yielded the most unstable re-
sults and was thus not included in the final assessment
of RQ values.
Statistical analysis
Analyses of the microarray data were performed using
BRB-ArrayTools Software developed by Dr. Richard Simon
and BRB-ArrayTools Development Team [8]. After quan-
tile normalization of the samples, we excluded one fourth
of the genes showing minimal variation across our dataset.
In order to assess gene expression profiles predictive of
bevacizumab benefit, we utilized Compound Covariate
Predictor, Diagonal Linear Discriminant Analysis, Nearest
Neighbor Classification, Support Vector Machines with
linear kernel and Bayesian Compound Covariate Pre-
dictor. These algorithms incorporate genes differentially
expressed among different classes as assessed by the ran-
dom variance t-test. Evaluation of the predictive value of
these methods was based on Leave-One-Out-Cross-Valid-
ation. The 8-month Progression-Free status was used as
endpoint and surrogate marker of bevacizumab benefit.
For all the markers the median (50th percentile) were
examined as possible threshold for prognostic signifi-
cance categorizing the gene expression levels into high
versus low. The expression of five genes was examined
for correlation to the following parameters as endpoints:
a) Objective response rate (ORR- Best response to
therapy; complete or partial response), prior to any metas-
tasectomy, b) Progression-free survival (PFS), calculated
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sion, death or last follow-up, whichever occurs first.
ORR was chosen as an objective, easy to measure end-
point which is not confounded by the potentially cura-
tive resection of metastases in some patients. On the
other hand, PFS was used as a survival endpoint in order
to investigate the possible association of genes with sur-
vival, without impact on tumor regression rates.
The Fisher’s exact test was used to examine possible as-
sociations between gene expressions with the overall re-
sponse rate (ORR), while odds ratios were also calculated
in order to measure the association. Time-to-event distri-
butions were estimated using the Kaplan-Meier curves.
The log-rank test and Cox’s proportional hazards models
was used to examine the univariate prognostic significance
of the markers for PFS. For all univariate tests the signifi-
cance level was set at α = 0.05. Multivariate analysis in-
cluded clinical parameters and gene expression profiles
that were significant in the univariate setting. The SAS
software was used for statistical analysis (SAS for Win-
dows, version 9.3, SAS Institute Inc., Cary, NC, USA).
Results
Microarray identification of candidate genes in the Test set
The sixteen patients in the Test set had metastatic colon
cancer treated with FOLFIRI + bevacizumab (n = 13)













Progressive disease within 8 months
Microarray analysis
Gene Name
KLF12 Kruppel-like factor 12
AGR2 Anterior gradient homolog 2 (Xe
ALDH6A1 Aldehyde dehydrogenase 6 famil
MCM5 Minichromosome maintenance co
TFF2 Trefoil factor 2achieved a complete remission and nine a partial remission
(objective response rate, ORR 75.0%). Ten patients (62.6%)
remained progression-free for at least eight months. Pa-
tient and tumor characteristics are shown in Table 1. The
8-month Progression-Free status was used as the endpoint
for examining the association of genome-wide gene expres-
sion with it as a surrogate marker of bevacizumab activity.
In this test set, we developed gene expression models using
different algorithms to predict which patients would pro-
gress within 8 months. The optimal predictor comprised
of five genes, differentially expressed between patients
who had progressed within 8 months and those who
remained progression free at that time point, at a signifi-
cance level of 0.00005 (random variance t-test). Prediction
accuracies fluctuated between 89–94%, based on the five
different algorithms. Tumor tissue samples from patients
with unfavorable PFS status were found to overexpress
four out of the five genes (AGR2, ALDH6A1, TFF2,
MCM5) and underexpress KLF12. Information on the
five-gene model can be found in Table 1 and Figure 1.
Application of the 5-gene predictor with qPCR in the
Bevacizumab qPCR and Control sets
Application of the 5 genes of the predictor in the Test
set yielded significant associations with PFS in the
predicted direction for individual markers AGR2,
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Figure 1 Gene clustering in microarray analysis of test set according to 8-month progression-free endpoint. Hierarchical clustering was
performed using the euclidean distance and the average linkage algorithm. UPPER ROW-PD8m: Progressive disease during first 8 months from
treatment start, noPD8m: Progression-free during 8 months from treatment start. LOWER ROW- Patient tumor samples (n = 16, two patients
ineligible). VERTICAL LEFT: Expression of five genes. Red denotes overexpression, Green denotes underexpression.
Table 2 Patient demographics in Bevacizumab qPCR and
Control sets
Variable Set
Control Bev qPCR P-value
Patients N 72 49
Age Median 64.5 60.1 0.0543
Range 41-77 32-77




42 (58.3) 23 (46.9) 0.1084
Oxaliplatin-based
regimen
16 (22.2) 21 (42.9)
Both irinotecan and
oxaliplatin
5 (6.9) 1 (2.0)
Fluoropyrimidine only 2 (2.8) 2 (4.1)
Erbitux only 7 (9.7) 2 (4.1)
Best response CR 5 (6.9) 1 (2.0) 0.5364
PR 26 (36.1) 17 (34.7)
SD 16 (22.2) 14 (28.6)
PD 9 (12.5) 10 (20.4)
NE/Missing
Data
16 (22.3) 7 (14.3)
Histological grade 1-2 50 (69.4) 34 (69.4) 0.8638
3-4 19 (26.4) 12 (24.4)
Primary site Left 54 (75.0) 35 (71.4) 0.6619
Right 18 (25.0) 14 (28.6)
Gender Female 24 (33.3) 24 (49.0) 0.0842
Male 48 (66.7) 25 (51.0)
Stage at biopsy I-III 25 (34.8) 16 (32.6) 0.8962
IV 46 (63.8) 31 (63.2)
8-month progression-free
rate
39 (54.2) 25 (51.0) 0.6352
Metastasectomy 6 (8.3) 7 (14.3) 0.5480
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dian cut-off ) but none for KLF12 (Additional file 2:
Figure S2). Predetermined clustering of RQ values for
the same genes according to the predictor pattern was
not possible for the 16 tumors in this set, since no
groups applicable for statistics could be formed. There-
fore, the Test set could not be used for the evaluation of
the predictor with qPCR.
Demographics
In the Bevacizumab qPCR set, forty-nine patients with
metastatic colon cancer, of a median age of 60.1 years, re-
ceived mostly irinotecan- or oxaliplatin-based regimens
combined with bevacizumab as first-line therapy. An ob-
jective response was seen in 36.7% of them, while 51.0%
were free from progression for at least 8 months. Seven
patients (14.3%) underwent potentially curative metasta-
sectomies following therapy-induced cytoreduction. In the
control set, seventy-two advanced colon cancer patients of
a median age of 64.5 years received mostly irinotecan-
based chemotherapy (58.3%) or oxaliplatin-based regi-
mens as first-line therapy. No bevacizumab was adminis-
tered. An objective response was seen in 43.1% of them,
while 54.2% were free from progression for at least
8 months. Six patients (8.3%) underwent potentially cura-
tive metastasectomies following therapy-induced cytore-
duction. Most characteristics of the Bevacizumab qPCR
and Control sets were matched and are shown in Table 2.
ORR
The expression of five selected genes individually as well
as the complex expression profiles of gene combinations
were studied for association with objective response rate.
Only the expression profile of ALDH6A1 + TFF2 +
MCM5 correlated strongly with response to bevacizumab
(see Table 3). Among patients harboring tumors with
(ALDH6A1 +TFF2 +MCM5)-all low gene expression,
85.7% responded to bevacizumab chemoimmunotherapy
in the Bevacizumab qPCR set versus only 28.6% of those
with any other (ALDH6A1 + TFF2 +MCM5) expression
profile (p = 0.007). In the Control set, only 36.4% ofpatients harboring (ALDH6A1 + TFF2 +MCM5)-all low
tumors responded to chemotherapy-only, compared to a
rather similar ORR of 44.3% in patients with any other
(ALDH6A1 +TFF2 +MCM5) expression profile (p =
0.747). The Odds Ratio for Response in patients with
Table 3 Gene expession associated with patient outcomes




All low 4/11 (36.4%) 0.747 6/7 (85.7%) 0.007










high + TFF2 low)
1.29 0.39 2.92 0.03
ALDH6A1 + TFF2
Other vs. All low 1.76 0.0404 0.89 0.7406
*Critical point for the significance of p-values is a = 0.05/(N of comparisons) = 0.05/
27 = 0.001852 (Bonferroni correction).
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any other (ALDH6A1 + TFF2 +MCM5) profile was 0.72
(p = 0.63) in the Control set, but was 15.00 (p = 0.0168) in
the Bevacizumab qPCR set. The distribution of patients
with tumor regression, stable and progressive disease ac-
cording to the (ALDH6A1 + TFF2 +MCM5) expression
profile is visualized in Figure 2 for the Bevacizumab qPCR
set. Of note, low expression of the MCM5 gene also co-
rrelated significantly, though less strongly, with ORR
(MCM5-low tumors: Bevacizumab qPCR set, ORR 52.0%,
p = 0.038 - Control set, ORR 38.9%, p = 0.63).Figure 2 Objective response rate by (ALDH6A1 + TFF2 +MCM5) genePFS
When we examined the association of expression of our
five genes with PFS, a different picture emerged. In the
Bevacizumab qPCR set, patients with (KLF12-high +
TFF2-low) tumors had superior PFS (median 14 months,
95% CI 2-21) compared to patients with any other
(KLF12 + TFF2) expression profile (median PFS 7 months,
95% CI 5-10, p = 0.021, Figure 3). On the contrary, pa-
tients not treated with bevacizumab in the Control set had
a median PFS of 11 months (95% CI 8-13) when harboring
(KLF12-high + TFF2-low) tumors, not significantly differ-
ent from the median PFS of 8 months (95% CI 7-10) of
patients with any other (KLF12 + TFF2) expression profile
(p = 0.38). The Hazard Ratio for risk of progression for
any other (KLF12 + TFF2) expression profile versus the
reference category of (KLF12-high + TFF2-low) tumors
was 2.92 (p = 0.03) in the presence of bevacizumab and
1.29 (p = 0.39) in the absence of bevacizumab.
Of note, the profile of (ALDH6A1 + TFF2 +MCM5)
expression did not show any significant association with
PFS, while that of (KLF12 + TFF2) no association with
tumor response (ORR). Finally, the profile of all-low
(ALDH6A1 + TFF2) tumor gene expression showed a
marginally significant association with superior survival
in the chemotherapy-only Control set, but not in the
Bevacizumab qPCR set (Table 3). Detailed information
on all examined qPCR gene expression profiles in all sets
are given in Additional file 3: Table S1 and Additional
file 4: Table S2.
Multivariate analysis
A multivariate analysis model incorporating perform-





Figure 3 Progression-free survival by KLF12 + TFF2 gene expression. a) Control set. b) Bevacizumab qPCR set.
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omy and gene expression profiles significant in univari-
ate analyses was applied in the total population of
Bevacizumab qPCR and Control sets. No single gene or
complex multigene tumor expression profile showed any
independent significant association with either ORR or
PFS. Parameters with independent prognostic signifi-
cance for PFS were poor performance status (PS 2-3 vs
0-1, HR for disease progression 18.2, p = 0.0004) andoccurrence of metastasectomy (HR for disease progres-
sion 0.04, p = 0.0015).
Discussion
Our microarray-based exploratory study identified the
expression of five genes with significant correlation to
the probability of disease control from bevacizumab
therapy beyond the 8-month benchmark duration.
KLF12 (Kruppel-like factor 12) is located at 13q22,
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tein family of transcription factors. It represses the ex-
pression of the Activator protein-2 alpha (AP-2 alpha)
gene, an important regulator of vertebrate development
and carcinogenesis, by binding its promoter [9]. As a
transcription factor, overexpression of KLF12 in endo-
metrial cancer cell lines significantly repressed prolife-
ration and secretion of pro-survival factors such as
insulin-like growth factor binding protein-1 [10]. On the
other hand, KLF12 was shown to induce cell prolifera-
tion, angiogenesis and invasion in gastric cancer cell
lines and clinical samples [11]. High KLF12 gene expes-
sion may constitute a surrogate marker of tumors with
high proliferative, angiogenic and migratory potential,
amenable to VEGF blockade.
TFF2 (Trefoil Factor 2) is located at 21q22.3 and en-
codes a stable secretory protein, member of the Trefoil
family, expressed in gastrointestinal mucosa. Their func-
tions are not defined, but they may protect the mucosa
from insults [12]. Breast, pancreas and bile duct cancer
cell line experiments suggested that TFF2 expression in-
duces cell migration via Platelet-Activation Receptor 4
(PAR4) and Panc1 activation, as well as mitosis via
EGFR/MAPK axis signaling [13-17]. On the other hand,
TFF2 was shown to possess anti-inflammatory properties
and to undergo promoter methylation during gastric
cancer progression, data pointing to a tumor-suppressive
function [18,19]. ALDH6A1 (aldehyde dehydrogenase
6 family, member A1) was mapped at 14q24.3. The
encoded protein is a mitochondrial methylmalonate
semialdehyde dehydrogenase that plays a role in the val-
ine and pyrimidine catabolic pathways. This protein cat-
alyzes the irreversible oxidative decarboxylation of
malonate and methylmalonate semialdehydes to acetyl-
and propionyl-CoA [20,21]. Despite its regulatory role in
mitochondrial energy production and DNA catabolism,
no studies examined its putative contribution to cancer
homeostasis to date.
MCM5 (minichromosome maintenance complex com-
ponent 5) at 22q13.1 encodes for a member of the
MCM family of chromatin-binding proteins that stimu-
lates cell transition from G0 to G1/S phase of the cell
cycle and actively participates in cell cycle regulation
[22,23]. Data from clinical and preclinical models of
skin, esophageal, bladder and gastrointestinal carcin-
omas further confirm the proliferative, migratory and
cell cycle activating properties of the MCM5 protein
[24-27]. Low MCM5 gene expression could mark
tumors with low proliferation, abnormal vasculature
and hypoxia, the profile most amenable to vessel
normalization and cell kill by bevacizumab + chemother-
apy. Of note, the most well studied pro-oncogenic gene,
AGR2 (Anterior Gradient 2, at 7p21.3) which has
identified oncogenic functions such as attenuation ofendoplasmic reticulum stress, transition from G0 to G1
phase, inhibition of cell senescence and association with
tumor stage, was not found to correlate with either
response or progression-free survival in the validation
control [28].
We selected a «three-stage» design for our experiment,
which should be viewed as hypothesis-generating, rather
than proof of principle. First, we used data mining in order
to identify genes with potential association with bevacizu-
mab benefit from a test set of 16 patients for whom
genome-wide gene expression was studied in a microarray
platform. Second, we tested the predictive performance of
the 5 genes in the microarray predictor with qPCR, a
method more convenient and realistic for clinical practice,
in the test set and in an independent Bevacizumab qPCR
set of 49 patients who had been treated with bevacizumab.
Third, we used the same qPCR approach in order to
examine the prognostic significance of the predictor genes
in a matched control set of 72 patients who received first-
line chemotherapy, but not bevacizumab. We chose to in-
clude patients who had metastasectomy after chemother-
apy in both cohorts, despite introducing a positive bias:
surgical resection of metastases could alter the natural
course of disease and be a confounding factor in our
search for a predictor of bevacizumab benefit. However,
excluding metastasectomy cases would introduce a nega-
tive bias, as it is likely that patients led to potentially cura-
tive metastasectomy would be the ones with major
cytoreduction and disease control from chemotherapy +
bevacizumab. Accordingly, we used two metrics for clin-
ical benefit: best tumor response before metastasectomy,
which is not confounded by the latter, and progression-
free survival, which is more sensitive than overall survival
but potentially influenced by metastasectomy. Of note, the
incidence of metastasectomy was not significantly differ-
ent in the Bevacizumab qPCR and Control cohorts. We
failed to identify any qPCR gene signature that could in-
corporate all five genes identified in the Test set, conse-
quently our Bevacizumab qPCR cohort should not be
viewed as a «validation» cohort but as an exploratory co-
hort for the study of a new qPCR signature consisting of
some of the preselected five genes.
The conflicting function of genes studied reported by
other investigators maybe due to differences in cancer
types, tumor microenviroment, expression of multiple
other modulating biomolecules, disease stage as well as
study design and experimental methodologies. They
constitute the interpretation of observed associations of
genes with bevacizumab activity extremely difficult, es-
pecially in view of lack of constistency when various
benefit metrics are examined (response rate, PFS) and
the absence of independent significance in multivariate
analyses. The inability of our response-predictive qPCR
profiles to impact on PFS and vice versa surely raises
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coupling of ORR from PFS benefit may be due to the
impact of metastasectomies on PFS [29]. It could also be
explained by the commonly reported discrete biologies
underlying the phenomena of tumor regression and of
control of tumor proliferation, invasion and virulence,
especially when anti-angiogenic therapies are adminis-
tered [30,31]. Technical differences regarding RNA (mi-
croarrays) and mRNA (qPCR) sequence detection could
also account for the inability to successfully recapitulate
the entire 5-gene microarray predictor with qPCR. In
view of the multiple analyses performed (see Additional
file 3: Table S1 and Additional file 4: Table S2), it is not
safe to conclude that the association of our qPCR pro-
files with clinical benefit from bevacizumab may be
reflecting important functional roles of these genes or
establish them as surrogate markers of genetic subsets of
tumors responsive to anti-angiogenesis. These associa-
tions could simply constitute random findings and the
data should only be viewed as hypothesis-generating.
Although the search for a validated gene signature pre-
dictive for bevacizumab benefit did not bear fruit, some
findings are consistently reported. Gene expression profil-
ing studies in bevacizumab-treated patients with glioblast-
omas, breast and colon cancer identified predictive gene
signatures with little or no gene overlap which possessed
however a common repertoire of the gene functional on-
tologies implicated: cell proliferation, mitochondrial en-
ergy production, lipid metabolism, migration/invasion,
hypoxia regulation and immune response [32-35]. The
genes identified here are also characterized by the func-
tional roles above. Brauer et al suggested that a genetic
profile predictive for benefit from anti-angiogenesis may
be independent of tumor primary, while Fiebig at al could
not assign a known function in 59% of the 35 genes
predicting for bevacizumab benefit in colorectal cancer xe-
nografts and clinical samples [33,34]. Hu et al reported
that although a change in multigene expession in 21
bevacizumab-treated glioblastoma patients correlated to
outcome, they could not identify a baseline gene expres-
sion signature with prognostic significance. In our case,
only gene expression data at baseline were available [36].
Conclusions
To conclude, we identified two distinct qPCR gene ex-
pression profiles correlating with response (low ex-
pression of ALDH6A1 + TFF2 +MCM5) and with PFS
(KLF12-high + TFF2-low) in advanced colon cancer pa-
tients managed with bevacizumab and chemotherapy.
Despite our three-cohort experimental design, the mod-
erate sample size, the plethora of variables under study
and of analyses performed preclude us from establishing
a predictive utillity for these genetic profiles before fur-
ther validation in independent cohorts.Additional files
Additional file 1: Figure S1. REMARK diagram.
Additional file 2: Figure S2. Performance of all 5 genes of the
microarray predictor in the test, validation and control sets with respect
to patient PFS. AGR2, ALDH6A1 and MCM2 were consistent with the
predictor in the test set but not in the validation set; instead, 2 out of 3
genes were associated with longer PFS in the non-bevacizumab treated
cohort. TFF2 was consistent with the predictor in the test and validation
sets. KLF12 was the only gene that could not be validated in the test set
with qPCR; high transcript levels of this gene were, however, showed a
trend for better outcome in the validation set. Based on these findings
and upon failure to transfer the entire 5-gene signature into a single
qPCR profile, KLF12 and TFF2 RQ values were profiled for assessing their
possible value in predicting PFS upon bevacizumab treatment.
Additional file 3: Table S1. Univariate Cox regression for each qPCR gene
expression and their combinations among dataset groups in terms of PFS.
Additional file 4: Table S2. Fisher’s exact test for each qPCR gene
expression and their combinations among dataset groups in terms of ORR.
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